Research Article

Preventing White Adipocyte Browning during Differentiation In Vitro: The Effect of Differentiation Protocols on Metabolic and Mitochondrial Phenotypes

Elena Herbers,1 Mimmi Patrikoski,1 Anita Wagner,2,3 Riikka Jokinen,1 Antti Hassinen,4 Sini Heinonen,1 Susanna Miettinen5,6 Hilkka Peltoniemi,7 Eija Pirinen,2,3 and Kirsi H. Pietiläinen1,8

1Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
2Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
3Research Unit for Internal Medicine, Faculty of Medicine, University of Oulu, FIN-90220 Oulu, Finland
4Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
5Adult Stem Cells Group, Faculty of Medicine and Health Technologies, Tampere University, Tampere, Finland
6Research, Development and Innovation Center, Tampere University Hospital, Tampere, Finland
7Tilkka Hospital, Helsinki, Finland
8Obesity Center, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Correspondence should be addressed to Kirsi H. Pietiläinen; kirsi.pietilainen@helsinki.fi

Received 28 September 2021; Accepted 1 March 2022; Published 5 April 2022

Mitochondrial dysfunction in white adipose tissue is strongly associated with obesity and its metabolic complications, which are important health challenges worldwide. Human adipose-derived stromal/stem cells (hASCs) are a promising tool to investigate the underlying mechanisms of such mitochondrial dysfunction and to subsequently provide knowledge for the development of treatments for obesity-related pathologies. A substantial obstacle in using hASCs is that the key compounds for adipogenic differentiation in vitro increase mitochondrial uncoupling, biogenesis, and activity, which are the signature features of brown adipocytes, thus altering the white adipocyte phenotype towards brown-like cells. Additionally, commonly used protocols for hASC adipogenic differentiation exhibit high variation in their composition of media, and a systematic comparison of their effect on mitochondria is missing. Here, we compared the five widely used adipogenic differentiation protocols for their effect on metabolic and mitochondrial phenotypes to identify a protocol that enables in vitro differentiation of white adipocytes. We developed a workflow that included functional assays and morphological analysis of mitochondria and lipid droplets. We observed that triiodothyronine- or indomethacin-containing media and commercially available adipogenic media induced browning during in vitro differentiation of white adipocytes. However, the differentiation protocol containing 1 μM of the peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone prevented the browning effect and would be proposed for adipogenic differentiation protocol for hASCs to induce a white adipocyte phenotype. Preserving the white adipocyte phenotype in vitro is a crucial step for the study of obesity and associated metabolic diseases, adipose tissue pathologies, such as lipodystrophies, possible therapeutic compounds, and basic adipose tissue physiology.
1. Introduction

Increasing rates of obesity and its associated metabolic comorbidities are important challenges for healthcare systems and have considerable social and economic impacts [1, 2]. The exact mechanisms by which obesity leads to impaired metabolic health are still poorly understood, but abnormal function of white adipose tissue (WAT) is considered to be a major driver of these changes [3–5]. Importantly, a growing body of evidence suggests that mitochondrial dysfunction is associated with an impaired WAT phenotype in obesity [6–9].

Mitochondria are subcellular organelles that produce aerobic energy through oxidative phosphorylation (OXPHOS). Mitochondria are crucial for adipocyte differentiation (adipogenesis) and for the main adipocyte functions, such as oxidation of fatty acids (FA), glucose, and branched-chain amino acid (BCAAs) [10–16]. The fact that these processes are downregulated in WAT in obesity and associated with mitochondrial dysfunction highlights the important role of mitochondria in adipose tissue [17–25]. Recent animal studies have shown that mitochondrial activation in WAT can be potentially used as a therapeutic strategy for obesity and metabolic disorders [26]. Activating WAT mitochondria can lead to browning of white adipocytes (i.e., acquisition of brown adipocyte features). Brown adipocytes are characterized by a dense mitochondrial network, increased mitochondrial number and respiration, uncoupling 1- (UCP1-) mediated thermogenesis, and elevated FA oxidation (FAO) [27–29]. The therapeutic effect of white adipocyte browning is based on increased oxidative and uncoupling capacity of mitochondria. However, only few studies have been conducted on mitochondrial activation in white adipocytes in humans, and further investigations are necessary.

The current bottleneck in the development of WAT mitochondrial activating compounds is the lack of proper white adipocyte in vitro models. Mouse 3T3-L1 cells, human Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes, and primary stromal/stem cells derived from umbilical cord blood, bone marrow, or adipose tissue are currently the most extensively used in vitro models [30, 31]. Human primary adipose stromal/stem cells (hASCs) are easily accessible, capable of adipogenic differentiation in vitro, preserve donor- and depot-specific differences, and therefore are a promising tool for obesity research [32, 33]. However, the great diversity of hASC adipogenic differentiation protocols, including varying components and their concentrations and induction time, significantly limits the utilization and reproducibility of hASCs as an in vitro model (Supplementary Table 1). A substantial challenge is that some of the common compounds in adipogenic differentiation media, such as PPARy agonists and triiodothyronine (T3), can induce browning of in vitro-differentiated white adipocytes by boosting mitochondrial uncoupling, biogenesis, and activity and subsequently alter the metabolic profile of the cells [9, 34–40]. Minimizing browning and preserving the original adipocyte phenotype are essential when studying white adipocyte biology and mitochondrial function. To date, the mechanisms behind the browning effect of adipogenic compounds remain to be elucidated, and a direct comparison of the various differentiation protocols on mitochondrial and adipocyte phenotypes has not been performed.

In this study, we investigated the effect of the commonly used white adipocyte differentiation protocols on the white adipocyte metabolic and mitochondrial phenotype. We used a robust workflow to evaluate lipid and mitochondrial parameters to identify the optimal in vitro differentiation conditions without excessive browning effect on the adipocytes. Our study revealed elevated browning markers in differentiation protocols where T3 or indomethacin (INDO) has been added to the media and also in the protocol where commercial media were used. In contrast, low doses and a short induction period with the PPARy agonist rosiglitazone (Rosi) ensured an efficient differentiation with a minimal browning effect. We suggest an optimal differentiation cocktail for human white adipocytes that limits browning and ensures a reliable utilization of hASCs in obesity research.

2. Materials and Methods

2.1. Reagents. All reagents used in cell culture and assays were obtained from Sigma-Aldrich (St. Louis, Missouri, USA) if not otherwise specified.

2.2. Characteristics of the WAT Sample Donors. Subcutaneous WAT samples were acquired from the abdominal area during an elective liposuction operation in Tilkka Hospital, Helsinki. The samples were obtained from 6 healthy female donors (age 38.6 ± 6.9 years) with BMI = 23.4 ± 2.6. All participants provided written informed consent. The study protocol was approved by the Ethics Committee of Helsinki University Hospital (HUS/1039/2019).

2.3. Isolation and Culture of hASCs. Subcutaneous WAT was immediately dissected from fibrous material and blood vessels after the surgery and transported to the laboratory. hASCs were extracted by using a mechanical and enzymatic isolation method as described earlier [41, 42]. Briefly, samples were minced into small fragments and digested in DMEM/F12 containing collagenase type 1 (1.5 mg/ml, Thermo Fisher Scientific) for 60–90 minutes with gentle shaking. The resulting cell suspension was centrifuged for 10 minutes at 600 × g, and the stromal vascular fraction was resuspended in growth medium containing 5% human serum (Biowest), 1% penicillin/streptomycin, and 1% GlutaMax (Thermo Fisher Scientific) seeded in tissue culture-treated T75 flasks, and cultured in the same medium at 37°C in 5% CO2. After 48 hours, the floating cells were washed out with PBS and growth medium was replaced. After reaching 80% confluence, cells were either passaged or frozen. The first passage after extraction was designated as passage 0, and cryopreserved cells in passages 2 to 5 were used in the experiments.

2.4. Adipogenic Differentiation of hASCs. The common differentiation conditions for white adipocytes are summarized in Supplementary Table 1. From these, we selected the five
Table 1: Human white adipocyte differentiation protocols compared in this study.

| Protocol source | P1 | P2 | P3 | P4 | P5 |
|-----------------|----|----|----|----|----|
| Protocol source  | Lee et al., 2013 modified 1 | Lee et al., 2013 modified 2 | Lee et al., 2013 modified 3 | Zhang et al., 2013 modified | ZenBio DM2 (commercial) |
| Total duration induction time | 21 days 7 days | 21 days 7 days | 21 days 7 days | 21 days 21 days | 21 days 7 days |
| Basic conditions | Medium | Induction DMEM/F12 | Maintenance DMEM/F12 | Induction DMEM/F12 | Maintenance DMEM/F12 | Induction DMEM/F12 | Maintenance DMEM/F12 | Induction DMEM/F12 | Maintenance DMEM/F12 | Induction DMEM/F12 | Maintenance DMEM/F12 |
| Serum | HS 3% | HS 3% | HS 3% | HS 3% | HS 3% | HS 3% | FBS | FBS |
| Insulin | 100 nM | 100 nM | 100 nM | 100 nM | 100 nM | 100 nM | Unknown | Unknown |
| Dexamethasone | 1 μM | 1 μM | 1 μM | 1 μM | 1 μM | 1 μM | 850 nM | Unknown |
| IBMX | 0.5 mM | 0.5 mM | 0.5 mM | 0.5 mM | 0.5 mM | 0.5 mM | Unknown | Unknown |
| Basic compounds | Rosiglitazone | 1 μM | 1 μM | 1 μM | 1 μM | 1 μM | 1 μM | Unknown | Unknown |
| | T3 | 2 nM | 10 μg/ml | 100 nM | Unknown | Unknown | Unknown | Unknown | Unknown |
| | Transferrin | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown |
| | Indomethacin | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown | Unknown |
| | Biotin | 33 μM | 33 μM | 33 μM | 33 μM | 33 μM | 33 μM | Unknown | Unknown |
| | Pantothenate | 17 μM | 17 μM | 17 μM | 17 μM | 17 μM | 17 μM | Unknown | Unknown |

DMEM/F12 = Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12; HS = human serum; FBS = fetal bovine serum; IBMX = 3-isobutyl-1-methylxanthine; T3 = triiodothyronine.
most regularly used protocols for our study (Table 1) with slight modifications to ensure uniform incubation times and basic compounds used (such as dexamethasone, IBMX, biotin, pantothenate, and serum type) between the protocols. We tested and compared protocols for their effects on mitochondrial and adipocyte-specific functions (Table 2). Adipogenic differentiation started on the second day of postconfluence (designated as Und), followed by an induction period (7 days) and maintenance period (14 days). Cells at day 21 of differentiation were used for experiments. For protocol 4, induction cocktail was used during the whole differentiation period as previously described [11, 43]. The maintenance medium was DMEM/F12 (Thermo Fisher Scientific) supplemented with 1% penicillin/streptomycin (Thermo Fisher Scientific), 1% GlutaMax (Thermo Fisher Scientific), 3% human serum (Biowest), 17 μM pantothenate, 33 μM biotin, 100 nM insulin, and 1 μM dexamethasone to standardize the basic conditions. We replaced FBS with human serum (HS) in protocols 1-4 to avoid xenobiotic compounds. For the induction period, the maintenance media were supplemented as follows. Protocol 1 (P1) was based on Lee and Fried [44] and contained maintenance medium supplemented with 1 μM Rosi (Calbiochem, San Diego, US), 2 nM T3, and 10 mg/ml transferrin. For protocol 2 (P2), T3 and transferrin were omitted. Protocol 3 (P3) was similar to P2, but Rosi concentration was decreased to 100 nM. Protocol 4 (P4) was based on Zhang et al. and supplemented with 850 nM insulin and 125 nM INDO [11]. For protocol 5 (P5), commercially available compounds were used (DM-2 and AM-1, ZenBio, USA). This medium contained DMEM/F12, FBS, penicillin, streptomycin, amphotericin B, biotin, pantothenate, insulin, dexamethasone, IBMX, and PPARy agonist, although the exact concentrations of medium compounds are unknown.

2.5. Oil Red O Staining. Intracellular lipid accumulation was evaluated with Oil Red O (ORO) staining as described previously [45]. Briefly, cells were washed with PBS and fixed for 1 hour with 4% paraformaldehyde in PBS (Alfa Aesar). Subsequently, cells were pretreated with 60% isopropanol and incubated with 0.2% ORO staining solution for 15 minutes at room temperature. After a wash with PBS, ORO was extracted by a 10-minute incubation with 100% isopropanol. Absorbance was then measured at 510 nm with a Spark microplate reader (Tecan Group Ltd., Switzerland). Prior to assay measurement, cell nuclei were stained with Hoechst 33342 (1:1000) and imaged with a plate reader microscope (Cytation5 (BioTek Instruments Inc., Vermont, U.S.). ORO assay results were normalized to cell number.

2.6. Gene Expression Analysis. Total RNA was extracted from the adipocytes of each of the protocols after in vitro differentiation for 21 days, from WAT, and from the mature adipocyte fraction (MAF) of the same subjects using the miRNeasy Mini Kit (QIAGEN, Venlo, Netherlands) according to the manufacturer’s instructions. RNA concentration was assessed with a spectrometer (DeNovix), and quality was evaluated with TapeStation (Agilent, Santa Clara, USA). Total RNA (2 μg) from each sample was reverse transcribed using the SuperScript VILO cDNA synthesis kit following the manufacturer’s instructions (Invitrogen). The mRNA levels of nuclear-encoded (ZIC1, TBX1, TMEM26, LEP, ADIPOQ, FABP4, PPARγ, PGC1α, PGC1β, UCP1, UCP2, CIDEA, LIPE, ACADM, and ACADS) and mitochondrial-encoded (MT-ND5, MT-COXI) genes (Supplementary Table 2) were analyzed using quantitative PCR (qPCR) amplification in a CFX Real-Time system (Bio-Rad) with SYBR-green Flash (Thermo Fisher) with the following thermoprofile: 7 minutes at 95°C followed by 40 cycles of a 2-step amplification (denaturation at 95°C for 10 seconds and annealing and elongation at 60°C for 30 seconds). 40 ng of cDNA and 0.5 μM primers were used for the reaction. Samples were measured in triplicate. The results were normalized to IPO8 and GUSB (Supplementary Table 2) housekeeping genes, and relative gene expression levels were calculated with the standard curve method using the qBASE (Biogazelle) software [46]. Primer sequences are available in Supplementary Table 2.

2.7. Assessment of Mitochondrial DNA Amount. Total cellular DNA was isolated using proteinase K and SDS lysis followed by phenol:chloroform extraction and ethanol precipitation [47]. Total DNA was quantified using Qubit Fluorometer (Thermo Fisher). The amounts of DNA from mitochondrial (MT-ND5, MT-CYT B) and nuclear (B2M, APP) (Supplementary Table 2) genome regions were analyzed by qPCR amplification in CFX Real-Time system with SYBR-green Flash (Thermo Fisher) with the following thermoprofile: 7 minutes at 95°C followed by 40 cycles of a 2-step amplification (denaturation at 95°C for 10 seconds and annealing and elongation at 60°C for 30 seconds). 10 and 1 ng of total DNA were used as a template for nuclear and mitochondrial genome region analyses, respectively, using 0.5 μM primer concentration. Samples were measured in triplicate. The ratio between mitochondrial DNA (mtDNA) and nuclear DNA amount was used to determine the mtDNA amount with the standard curve method using the

| Parameter                      | White | Brown |
|-------------------------------|-------|-------|
| Brown fat markers             | −     | +     |
| White fat markers             | +     | −     |
| Mitochondrial biogenesis      | +     | ++    |
| Mitochondrial mass            | +     | ++    |
| Mitochondrial fragmentation   | −     | +     |
| Mitochondrial oxidative capacity | +     | ++    |
| Uncoupling and thermogenesis  | −     | +     |
| Lipolysis and β-oxidation     | +     | ++    |
| Lipid droplet number          | +     | ++    |
| Lipid droplet size            | +++   | +     |
Finally, lipid droplet parameters were assessed as separate segmented subpopulations in the Bodipy (green).

2.10. Transmission Electron Microscopy. Cells were differentiated on cover slips and fixed in 0.1 μM sodium phosphate buffer pH 7.4 (A18139.14, VWR, Radnor, PA, USA) containing 2% glutaraldehyde for 1 hour at room temperature. Samples were processed following standard published methods and imaged with a Jeol JEM-1400 transmission electron microscope (TEM) (Jeol Ltd., Tokyo, Japan) operating at 80 kV [48]. Lipid droplets and mitochondrial parameters were analyzed using the Microscopy Image Browser (MIB) [49].

2.11. Mitochondrial Bioenergetic Profiling. Mitochondrial respiration was measured in differentiated adipocytes using the XF96e cellular flux analyzer (Seahorse Biosciences, North Billerica, MA, USA) using the Agilent Mito Stress Test. hASCs were seeded at a density 10000 cells per well and differentiated for 21 days. On the day of assay, maintenance medium was replaced with the Seahorse Assay medium supplemented with 10 mM glucose, 1 mM pyruvate, and 2 mM glutamine, and pH was adjusted to 7.4. Oxygen consumption rate (OCR) was measured at basal level and after addition of OXPHOS modulators, including proton leak after oligomycin (1 μM), maximal OCR after FCCP (2 μM), and nonmitochondrial respiration after antimycin A and rotenone (2 μM each). All parameters were calculated as described previously [50]. After the measurement, cell nuclei were stained with Hoechst 33342 (1:1000) and imaged with a plate reader microscope Cytation5 (BioTek Instruments Inc., Vermont, U.S.). Results were normalized to cell number.

2.12. Lipolysis. Lipolysis experiments were performed at day 21 of differentiation as described previously [51]. Briefly, cells were washed with PBS and reincubated with basal DMEM without serum for 2 hours at 37°C for serum starvation. For stimulated and basal lipolysis measurement, adipocytes were then incubated for 2 hours at 37°C with Hank’s Balanced Salt Solution (HBSS) containing 2% BSA (FA-free) with or without 1 μM of isoproterenol, respectively. Conditioned media were collected, and free glycerol concentrations were quantified using a commercial fluorometric assay (EnzyChrome™ Adipolysis assay kit, BioAssay Systems, Hayward, CA, USA). Results were normalized to protein content of the cell lysate using a BCA kit.

2.13. Adipokine Secretion. Total adiponectin and leptin levels in the cell culture supernatants were quantified with the Human Total Adiponectin Quantikine ELISA kit and Human Leptin Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA). Conditioned media were collected between days 14 and 21 and centrifuged to discard cell debris. The samples were diluted for leptin measurement 1:40 and for adiponectin measurement 1:10. The assay was performed according to the manufacturer’s instructions, and the absorbance was then measured at 450 nm with a Spark microplate reader (Tecan Group Ltd., Switzerland).
2.14. Statistics. Statistical analyses for the differences between the five protocols were performed by one-way ANOVA for multiple comparisons with the Tukey post hoc test using Prism GraphPad. Data are shown as mean with error bars representing SEM. Associations between the differentiation ratio and adipogenesis gene expression was performed using the Pearson correlation in Prism GraphPad.

3. Results

3.1. Comparison of Human White Adipocyte Differentiation Protocols In Vitro. This study included the five widely used adipocyte differentiation protocols, which were compared for their effects on adipocyte phenotype and mitochondrial uncoupling, biogenesis, morphology, and function (Table 2). As shown in Supplementary Table 1, the composition of differentiation media varied greatly between these commonly used protocols. We focused on comparing the following differentiation protocols: insulin 100 nM+Rosi 1 μM+T3 +transferrin (P1), insulin 100 nM+Rosi 1 μM (P2), insulin 100 nM+Rosi 100 nM (P3), and insulin 850 nM+no Rosi +NDO (P4) (Table 1). In addition, we included one commonly used commercial differentiation medium (P5), which contains an unspecified PPARγ agonist with unknown concentration as an inducer of differentiation. The concentrations of basic compounds, such as dexamethasone, IBMX, biotin, and pantothenate, were the same in all tested protocols, and their concentrations were based on the commonly used protocols (Supplementary Table 1).

3.2. Differentiation Capacity, Lipid Accumulation, and Lipid Droplet Parameters. The main criteria for efficient adipogenic differentiation traditionally include good differentiation capacity, high lipid accumulation, and formation of large unilocular lipid droplets. Lipid droplet morphology is a distinct feature between white and brown adipocytes. White in vitro-differentiated adipocytes develop large unilocular lipid droplets that occupy nearly the whole cell area, whereas brown adipocytes form multilocular smaller droplets [27–29]. To test whether all protocols successfully induce adipogenic differentiation, we assessed the ratio of differentiated adipocytes to total cell number using immunocytochemistry (ICC) (Figures 1(a) and 1(b), Supplementary Figure 1(a)). The lowest differentiation ratio was observed in P3 (Figure 1(b)), suggesting that Rosi at concentration 100 μM was not sufficient to stimulate appropriate differentiation, whereas the other protocols successfully differentiated hASCs into adipocytes. Lipid quantification with both ORO- and Bodipy-based methods showed a significant lipid accumulation compared to undifferentiated cells in all protocols except P3 (Figures 1(c) and 1(d)). We used TEM (Figure 1(a)) to further analyze lipid droplet parameters, including the number and size of lipid droplets per cell and the area that lipids occupied in the cell. While P4-differentiated adipocytes had the highest number of lipid droplets per cell (Figure 1(e)), the droplets were significantly smaller and showed a lower cell area occupied by the droplets compared with other protocols as measured by both ICC and TEM (Figures 1(f) and 1(g), Supplementary Figure 1(b)–(c)). The relative frequency of lipid droplet populations by area showed that most P4 droplets had an area distributed between 1 and 20 μm without large droplets over 50 μm. Although all adipocytes differentiated with the P1, P2, P3, and P5 protocols developed large lipid droplets, the P1 and P2 protocol adipocytes had the greatest proportion of droplets over 100 μm (Figure 1(h)). Taken together, these results indicate that the INDO-based differentiation protocol (P4) induces brown-like multilocular white adipocytes, while P2 (Rosi) and P1 (Rosi+T3) protocols generate the whitest adipocytes based on lipid droplet parameters.

3.3. Gene Expression Profiles of Differentiated Adipocytes. To confirm adipogenic differentiation on a gene expression level, we analyzed the expression of the key adipogenic markers PPARγ, ADIPOQ, and FABP4 (Figures 2(a)–2(c)). The transcript levels demonstrated a moderate correlation with the differentiation ratio data (Figures 1(b) and Figures 2(d)–2(f)), showing the highest expression of the adipogenic markers in P4 and the lowest in P3. We also measured the adiponectin secretion into cell culture medium, which confirmed the ADIPOQ expression data (Figure 2(g) (g)). Next, we asked which of the tested protocols is the most browning neutral. For this, we first analyzed the gene expression markers of brown adipocytes [38, 52–55]. We did not detect any expression of brown adipocyte markers ZIC1, TBX1, and TMEM26 in cells differentiated with any of the protocols (data not shown). However, levels of the browning marker CIDEA were significantly increased while levels of the white adipocyte marker LEPTIN were decreased with protocol P4, indicating browning with this protocol (Figures 3(a) and 3(b)). Similarly, leptin secretion was reduced in P4 (Figure 3(c)). Compared with white adipocyte mitochondria, brown adipocyte mitochondria exhibit elevated thermogenesis and FAO [56]. Therefore, we next assessed mRNA levels of the main uncoupling proteins and FAO enzymes. Expression of uncoupling proteins UCP1 and UCP2 was significantly upregulated only with protocol P4 (Figures 3(d) and 3(d)). We also analyzed the UCP1 expression on protein level with immunoblotting and found it significantly increased with protocol P4 (Figure 3(f)), in line with gene expression results (Figure 3(d)). To confirm these results with ex vivo samples, we compared the expression levels of UCP1 in in vitro-differentiated adipocytes to ex vivo subcutaneous WAT and MAF. Our findings confirmed that differentiation protocols P1-P3 and P5 did not induce UCP1 expression, as P1-P3 and P5 adipocytes exhibited similar UCP1 expression levels as subcutaneous WAT and MAF, in contrast to P4 adipocytes, where UCP1 expression levels were significantly higher than those in ex vivo WAT (Figure 3(g)). The mRNA levels of the key FAO enzymes ACADM and ACADS were increased with protocols P4 and P1, respectively (Figures 3(h) and 3(i)), indicating elevated FAO with these protocols. FAO in brown adipocytes depends on the availability of free FAs, which are generated through lipolysis along with the release of glycerol [57]. Gene expression levels of LIPE, a
Figure 1: Continued.
key enzyme involved in lipolysis, exhibited the same tendency as FAO enzymes (Figure 3(j)). Additionally, we analyzed the release of free glycerol into cell culture medium as an indirect measurement of lipolysis [35, 57]. We observed a significant increase (up to 4-fold) in isoproterenol-stimulated glycerol release in P1 and P5 compared with P2 and P3 (Figure 3(k)), suggesting a browning feature in P1 and P5 conditions compared to P2 and P3. Taken together, these data indicate that based on gene expression signature, lipolysis, and FAO, Rosi-based P2 and P3 are the most browning neutral protocols. In contrast, the INDO-based P4 differentiation protocol stimulates the most brown adipocyte-like phenotype (gene expression, lipolysis, and FAO). Increased lipolysis and FAO are also characteristics for P1 (Rosi+T3) and P5 (commercial).

3.4. Mitochondrial Bioenergetic Profile. Since increased mitochondrial respiration and uncoupling are hallmarks of brown adipocytes [9, 58], we measured mitochondrial bioenergetic profiles with a Seahorse analyzer (Figure 4(a)).
We did not detect any significant differences in basal respiration or ATP production between the protocols (Figures 4(b) and 4(c)). The protocol P3 and P5 adipocytes exhibited the lowest maximal respiration, proton leak (i.e., uncoupling), and spare respiratory capacity. In contrast, the P1 adipocytes had the highest maximal respiration, proton leak, and spare respiratory capacity (Figures 4(d)–4(f)) when compared with protocols P3 and P5. P2 and P4 adipocytes displayed a mitochondrial bioenergetic profile between the high and low groups. Moreover, coupling efficiency was lowest in P1 and P4 (Figure 4(g)), which suggests that the mitochondria of P1 and P4 adipocytes have low efficiency to couple electrons to ATP synthesis [50]. Overall, our data indicate that P2 (Rosi) induced a bioenergetic profile resembling that of white adipocytes, including moderate respiration level, proton leak, and high coupling efficiency.

3.5. Mitochondrial Biogenesis and Dynamics. Since the increased abundance of mitochondria is a hallmark of browning [35, 38], we next analyzed mitochondrial biogenesis using mtDNA amount as a readout. The amount of mtDNA was highest in P1 and P4 adipocytes (Figure 5(a)). We also quantified mitochondrial number in TEM images, which were significantly increased with P4 (Figure 5(b)). Additionally, we...
Figure 3: Continued.
measured the ratio of the mitochondrial area to lipid droplet area per cell. Consistent with our previous findings, this ratio was remarkably increased in P4, indicating the abundance of mitochondria over lipid content, the signature of brown-like adipocytes [29, 59] (Figure 5(c)). Using immunoblotting, we then evaluated mitochondrial mass based on mitochondrial outer membrane protein porin expression, which was significantly elevated with P4 compared with the other protocols (Figures 5(d) and 5(e)). Additionally, we analyzed protein levels of OXPHOS complex subunits (Figure 5(d)) and observed that these were significantly increased with P4 compared with other protocols (Supplementary Figure 2(a)–(d)). However, when protein levels were normalized per mitochondrion using the mitochondrial outer membrane protein porin as a loading control, the effect of the P4 protocol on OXPHOS complex subunits was lost (Supplementary Figure 2(e)–(h)). This suggests increased mitochondrial content in P4 but without an enrichment of OXPHOS complexes per mitochondrion.

To evaluate mitochondrial morphology, we analyzed the area, length, perimeter, and eccentricity of mitochondria profiles using TEM (Figure 5(f)). Mitochondrial morphology is a distinctive feature between brown and white adipocytes, as the mitochondrial network is mainly elongated (fusion prevailed) in white adipocytes, whereas the network in brown adipocytes is fragmented (fission prevailed) [27, 38]. Mitochondrial fission is crucial for brown adipocyte uncoupling and thermogenesis, while fusion is associated with more efficient ATP production [60]. We observed that P2- and P3-differentiated cells possess the most elongated mitochondria, which was evidenced by increased area, length, perimeter, and eccentricity (Figures 5(g)–5(j)). Eccentricity is the parameter of an object varying between 1 (object is a line) and 0 (object is a sphere). We observed
Figure 4: Effect of differentiation protocols on mitochondrial respiration. (a) Oxygen consumption rate (OCR) measured in adipocytes differentiated for 21 days with five differentiation media. Calculated average values of (b) basal respiration, (c) ATP production, (d) maximal respiration, (e) proton leak, (f) spare respiratory capacity, and (g) coupling efficiency (%) \( \left( \frac{ATP \text{ production}}{basal \text{ respiration}} \right) \times 100 \). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis \( (n = 6) \): * \( p < 0.05 \), ** \( p < 0.01 \). Error bars are shown as SEM.
Figure 5: Continued.
Figure 5: Effect of the differentiation protocols on mitochondrial mass and morphology. Human adipose-derived stem cells were differentiated for 21 days with five adipogenic differentiation protocols. (a) Relative mtDNA amount calculated as a ratio of the mitochondrial gene MT-CYTB to nuclear genes APP and B2M. Quantification of transmission electron microscopy (TEM) images: (b) number of mitochondrial profiles per image and (c) ratio of the mitochondrial area to lipid droplet area quantified with the Microscopy Image Browser (MIB). (d) Protein levels of vinculin, porin, and OXPHOS complex subunits NDUFB8 (CI), SDHB (CII), cytochrome c oxidase subunit 2 COXII (CIV), and ATP5A (CV) were analyzed by western blotting. (e) Quantification of porin level relative to vinculin. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis (n = 6): * p < 0.05, ** p < 0.01, **** p < 0.0001. Error bars are shown as SEM. (f) TEM images of mitochondria in undifferentiated hASCs and adipocytes differentiated with five protocols. Cells were imaged at 6000x magnification using a JEOL JEM-1400 electron microscope. Quantification of (g) mitochondrial area, (h) length, (i) perimeter, and (j) eccentricity with MIB. hASC3 was used for TEM analysis. At least 500 mitochondria were analyzed for each condition. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc analysis: *p < 0.05, **p < 0.01, and ****p < 0.0001. Error bars are shown as SEM. The statistical differences in (b), (c), (e), and (g) indicate a comparison with all the other protocols.
decreased mitochondrial eccentricity in P4 and especially in P1 and P5, suggesting a fragmentation of the mitochondrial network, a hallmark of browning (Figure 5(j)). The relatively small size of mitochondria in P1 and P5 could explain the enrichment of complex IV+I subunits observed in these protocols after normalization of protein levels to porin (Supplementary Figure 2(e)). Taken together, these results suggest that adipocytes differentiated with the INDO-based P4 protocol exhibit a brown adipocyte-like phenotype with an increased number of fragmented mitochondria. Additionally, mitochondrial fragmentation was detected in P1 (Rosi+T3) and P5 (commercial) protocols together. Instead, P2- and P3-differentiated adipocytes (Rosi) exhibited a white adipocyte mitochondrial phenotype.

3.6. The Mechanism Mediating the Effects on Mitochondrial Biogenesis. To study the mechanism driving the observed changes in mitochondrial biogenesis and dynamics, we analyzed levels of the key mitochondrial biogenesis regulators PGC1α and PGC1β. The expression level of PGC1α was significantly higher with protocols P4 and P5, but PGC1β was higher only in P4 compared to other conditions (Figures 6(a) and 6(b)). To confirm our results with ex vivo samples, we compared the expression levels of PGC1α in in vitro-differentiated adipocytes to ex vivo subcutaneous WAT and MAF. Our findings confirm that both P4 (INDO) and P5 (commercial) have higher expression levels of PGC1α than what is naturally occurring in ex vivo WAT and MAF (Figure 6(c)). Given that part of the mitochondrial proteins is encoded in the mitochondrial genome, we assessed the expression levels of two mtDNA-encoded transcripts, MT-ND5 and MT-COXI, which are downstream targets of PGC1α. We observed elevated expression levels of MT-COXI and MT-ND5 in P4 and P1 (Figures 6(d) and 6(e)). Taken together, our data indicate that increased mitochondrial biogenesis and its downstream effects on MT- gene expression with P4 (INDO) could result from the induction of PGC1α or PGC1β.

4. Discussion

In recent decades, mitochondria have been recognized as important regulators of white adipose tissue metabolic health, and mitochondrial dysfunction has been associated with obesity and related metabolic complications [7, 9, 61]. The availability and relative ease of adipogenic differentiation of hASCs make them an attractive tool to elucidate the mechanisms behind mitochondrial dysfunction in obesity and to study compounds to reactivate dysfunctional mitochondria. However, a marked limitation of white adipocytes in in vitro studies is the lack of a standardized differentiation protocol [34–40]. Despite the large number of hASC studies, a detailed characterization of the effects that differentiation methods have on the white adipocyte phenotype has not been performed before. In this study, we assessed the metabolic and mitochondrial phenotype of adipocytes differentiated with five widely used differentiation protocols. We propose that the best method for white adipocyte differentiation that does not induce browning of white adipocytes is the differentiation protocol that contains Rosi 1 μM (P2).

Adipogenic differentiation is a complex process that requires serial activation of transcription factors, among which the most crucial are peroxisome proliferator-activated receptor gamma (PPARγ) and the CCAAT/enhancer-binding protein (C/EBP) groups of genes [62, 63]. Insulin was discovered among the first adipogenic differentiation media compounds to induce spontaneous lipid accumulation in ASCs in vitro by activating phosphatidylinositol-3 kinase, AKT1/2, and mammalian targets of rapamycin pathways [60]. Furthermore, addition of dexamethasone and IBMX improves differentiation by stimulating the glucocorticoid receptor and cAMP signaling pathways, respectively [60, 64, 65]. These are standard compounds of adipogenic differentiation media (Supplementary Table 1) and were part of the tested differentiation protocols in this study.

Adipogenic differentiation in vitro is typically improved by the addition of the nonsteroidal anti-inflammatory drug INDO or thiazolidinediones such as Rosi. Both activate PPARγ, the master regulator of adipogenesis. INDO has been widely used for adipogenic differentiation of precursors from both white and brown fat depots [60, 66–71]. Typically, cells are exposed to INDO during the entire differentiation period, or the compound is used cyclically (Supplementary Table 1). Rosi is also an insulin sensitizer, which makes it one of the main compounds of adipogenic differentiation media. The use of Rosi during differentiation is highly variable among protocols (Supplementary Table 1). Another common compound is the thyroid hormone T3, which improves adipogenesis by binding to thyroid hormone receptor A [60]. T3 is regularly used in combination with Rosi and occasionally with INDO. Although T3 is generally applied only for the induction period, in some cases, it is used for both induction and maintenance (Supplementary Table 1). In this study, we investigated the effect of PPARγ agonists and T3 on the adipocyte metabolic and mitochondrial phenotype.

We compared differentiation protocols that include the PPARγ agonist Rosi (P2, P3) or an unspecified PPARγ agonist in commercial media (P5) during 7 days of induction. Compared with other adipogenic compounds, the effect of Rosi on the adipocyte and mitochondrial phenotype is the most studied [40, 72]. Rosi promotes white-to-brown adipocyte transdifferentiation in both rodents and humans by activation of mitochondrial biogenesis and function, FAO, and thermogenesis via UCP1 [34–38, 40]. However, the incubation period of Rosi appears to be crucial to induce browning. Greater than 9-day exposure to Rosi induces white-to-brown adipocyte conversion with abundant thermogenically active mitochondria [37, 55, 73]. We compared the effect of Rosi concentrations of 1 μM (P2) and 100 nM (P3) to identify the minimal dose to induce differentiation but prevent the browning effect. Induction for 7 days with 1 μM (P2) or 100 nM (P3) of Rosi did not affect gene expression of any browning markers or lipid metabolism. In both protocols, mitochondria possessed a mainly elongated network and the coupling efficiency of mitochondrial respiration was significantly higher compared to any other differentiation condition. However, the
Figure 6: Continued.
followed by Tukey’s post hoc analysis: *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars are shown as SEM. (f) Summary table indicating adipocyte and mitochondrial parameters in hASCs differentiated for 21 days with five adipogenic differentiation protocols.

| Parameter                  | Rosi 1µM+T3 | Rosi 1µM | Rosi 100nM | INDO | Commercial |
|----------------------------|-------------|----------|------------|------|------------|
| "Brown" gene markers       | ↑           | ↑        | ↓          | CIDEA, UCP1 | ↓          |
| "White" gene markers       | ↑           | ↑        | ↑          | ↑    | ↑          |
| Mito biogenesis            | ↑           | ↑        | ↓          | ↑    | ↑          |
| Mito mass, OXPHOS          | ↑           |          | ↓          | ↑    | ↓          |
| Mito fragmentation         | ↑↑          |          | ↑          | ↑    | ↑          |
| Oxidative capacity         | ↑           |          | ↓          | ↑    | ↑          |
| Uncoupling                 | ↑↑          |          | ↓          | ↑    | ↑          |
| Lipolysis and FA oxidation | ↑↑          |          | ↑          | ↑    | ↑          |
| Lipid droplets size        | ↑           | ↑        | ↓          | ↑    | ↑          |
| Different efficiency       | ↑           | ↑        | ↓          | ↑    | ↑          |

Figure 6: Expression levels of mitochondrial biogenesis and mtDNA-encoded genes. Human adipose-derived stem cells were differentiated for 21 days with five adipogenic differentiation protocols. Relative mRNA expression of nuclear-encoded genes (a) PGC1α and (b) PGC1β measured by RT-qPCR. (c) Relative mRNA expression of PGC1α in *in vitro*-differentiated adipocytes, white adipose tissue (WAT), and mature adipocyte fraction (MAF) of the same subjects measured by RT-qPCR. Relative mRNA expression of mitochondrial-encoded genes (d) MT-COXI and (e) MT-ND5 measured by RT-qPCR. Statistical analysis was performed using one-way ANOVA (n = 6) followed by Tukey’s post hoc analysis: *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars are shown as SEM. (f) Summary table indicating adipocyte and mitochondrial parameters in hASCs differentiated for 21 days with five adipogenic differentiation protocols.

The effect of INDO on mitochondria has not been extensively investigated. However, a recent study revealed a dose-dependent browning effect on 3T3-L1 cells and human primary brown and subcutaneous white adipocytes [74]. In contrast, Wang et al. reported that INDO decreased *UCP1* expression in cultures of human brown adipocytes [75]. In this study, the INDO-based protocol (P4) showed the highest differentiation efficiency. However, we observed increased expression of *UCP1*, *UCP2*, and *CIDEA*, together with a significant decrease on *LEPTIN*, which is a typical signature of *in vitro* browning of white adipocytes [40, 55, 73, 76]. Furthermore, we observed increased mitochondrial biogenesis and mass, mitochondrial network fragmentation, and reduced lipid droplet size, all of which are brown adipocyte features (Figure 5(e)). Thus, our data indicate that exposure to INDO during the whole differentiation period can lead to browning of white adipocytes, which might be dose dependent [74]. Traditionally, INDO is used in combination with IBMX and a high concentration of insulin to enhance differentiation [68] (Supplementary Table 1). Therefore, further studies are required to fully understand the effect of INDO for white adipocyte differentiation.

T3 increases basal metabolic rate and energy expenditure in brown adipocytes by direct stimulation of UCP1, UCP2, and lipolysis gene expression in brown adipocytes, human subcutaneous WAT, mature white adipocytes, and *in vitro*-differentiated subcutaneous adipocytes [77–80]. T3 used in white adipocyte differentiation media was shown to promote mitochondrial biogenesis via PGC1α and PGC1β, mtDNA replication and transcription, and oxygen consumption [39]. In line with Lee et al. [39], this study indicates that the T3-containing differentiation protocol (P1) resulted in increased mtDNA amount, mitochondrial respiration, lipolysis rate, and FAO-related gene expression. Moreover, we also observed that T3 induced a large fragmentation of the mitochondrial network and shifted respiration towards uncoupling (Figure 5(e)). A fragmented mitochondrial network is a brown adipocyte feature [27] and is crucial for thermogenesis and uncoupling [81–87]. As no such effect was detected in P2 containing the same compounds as P1 (except T3), this study suggests that T3 induces browning markers *in vitro*. However, unlike in the classical brown phenotype, thyroid hormones also increase lipid accumulation [88, 89], which was indicated in our study given that P1-differentiated cells formed the largest lipid droplets. Indeed, this could explain why T3 is commonly used for the differentiation of white adipocytes, likely neglecting its impact on mitochondrial parameters.

Lastly, we analyzed a commonly used commercial medium (P5) containing the same compounds as P2 and P3, such as Rosi, DEXA, and IBMX, although the exact
concentrations and the type of PPARy agonist are unknown. We observed that 7-day incubation with commercial medium strongly increased PGC1α expression, lipolysis rate, and mitochondrial fragmentation (Figure 5(e)). This could be explained by a possible high concentration of the PPARy agonist, the type of PPAR agonist used, or both. Overall, this protocol resulted in brown adipocyte-like features as T3 (P1) and INDO (P4) and therefore should be used with caution for in vitro differentiation of white adipocytes.

5. Conclusions

The lack of a uniform adipogenic protocol is a generally accepted limitation for the in vitro utilization of hASCs. In this study, we compared several protocols by setting up a workflow to extensively characterize adipocytes, their phenotype, functionality, and mitochondria. Our data revealed that commonly used differentiation protocols containing INDO, T3, and commercial media induced browning features in vitro and consequently should be used with caution when aimed at obtaining a pure culture of white adipocytes. Instead, we propose induction with 1 μM Rosi for 7 days (P2) as a standard differentiation protocol of white adipocytes to minimize the browning effect. Our findings will improve future research in obesity, specifically regarding the role of mitochondria in obesity development and potential treatments. Furthermore, our proposed protocol is beneficial for the study of other adipose tissue pathologies, such as lipodystrophies, and for basic adipocyte biology research.

Data Availability

Data may be available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

Acknowledgments

We thank all the volunteers for their valuable contributions, the staff members of the Tilika Hospital and Obesity Research Unit staff for assistance in laboratory work, Mervi Lindman and Taina M. Suntio from the electron microscopy unit for TEM samples preparation and imaging assistance, Ilya Belevich for TEM image analysis guidance, and the FIMM High Content Imaging and Analysis unit for HC imaging and analysis (HiLIFE, University of Helsinki, and Biocenter Finland). This work was supported by the Academy of Finland (335443, 314383, 266286, and 314455); Academy of Finland ProFilo (336449); Academy of Finland, Centre of Excellence in Research on Mitochondria, Metabolism and Disease (FINMIT) (272376); Finnish Medical Foundation; Gyllenberg Foundation; Novo Nordisk Foundation (NNF20OC0060547, NNF17OC0027232, and NNF10OC101354); Finnish Diabetes Research Foundation; Finnish Foundation for Cardiovascular Research; University of Helsinki and Helsinki University Hospital; Government Research Funds, Orion Research Foundation, and Paulo Foundation; and Finnish Medical Foundation TERVA funding.

Supplementary Materials

Supplementary Table 1: conditions used for induction of white adipocyte differentiation in publications. Supplementary Table 2: primer sequences for human genes used in this study. Supplementary Table 3: Harmony 4.9 image analysis pipeline. Supplementary Figure 1: fluorescent lipid droplet staining with Bodipy green and quantification of lipid droplet parameters with Harmony software. Supplementary Figure 2: quantification of the OXPHOS protein levels relative to vinculin and porin. Supplementary Figure 1: (a) human adipose-derived stem cells were differentiated for 21 days with five adipogenic differentiation protocols. Lipid droplets were stained with Bodipy green and the nucleus with Hoechst 33342, and cells were imaged at 5x magnification with a PerkinElmer Opera Phenix confocal microscope. All six cell lines are represented. Quantification of (b) lipid droplet area per cell and (c) lipid droplet mean size with Harley software. Lipid droplets were stained with Bodipy green and imaged at 5x magnification with a PerkinElmer Opera Phenix confocal microscope. Statistical analysis was performed using one-way ANOVA (n = 6) followed by Tukey’s post hoc analysis: *p < 0.05; **p < 0.01. Error bars are shown as SEM. Supplementary Figure 2: quantification of the (a) CIV+I, (b) CII, (c) CIII, and (d) CV protein levels relative to vinculin. Quantification of the (e) CIV+I, (f) CII, (g) CIII, and (h) CV protein levels relative to porin. Statistical analysis was performed using one-way ANOVA (n = 6) followed by Tukey’s post hoc analysis: *p < 0.05. Error bars are shown as SEM. The statistical differences in (c) and (d) indicate a comparison with all the other protocols. (Supplementary Materials)

References

[1] X. Pi-Sunyer, “The medical risks of obesity,” Postgraduate Medicine, vol. 121, no. 6, pp. 21–33, 2009.
[2] M. Bluher, “Obesity: global epidemiology and pathogenesis,” Nature Reviews. Endocrinology, vol. 15, no. 5, pp. 288–298, 2019.
[3] M. Bluher, “Adipose tissue dysfunction contributes to obesity related metabolic diseases,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 27, no. 2, pp. 163–177, 2013.
[4] P. Tandon, R. Wafer, and J. E. N. Minchin, “Adipose morphology and metabolic disease,” Journal of Experimental Biology, vol. 221, article jeb164970, Suppl 1, 2018.
[5] S. Virtue and A. Vidal-Puig, “Adipose tissue expandability, lipotoxicity and the metabolic syndrome – an allostatic perspective,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 338–349, 2010.
[6] A. De Pauw, S. Tejerina, M. Raes, J. Keijer, and T. Arnould, “Mitochondrial (dys)function in adipocyte (de)differentiation and systemic metabolic alterations,” The American Journal of Pathology, vol. 175, no. 3, pp. 927–939, 2009.
[7] S. Boudina and T. E. Graham, “Mitochondrial function/dysfunction in white adipose tissue,” Experimental Physiology, vol. 99, no. 9, pp. 1168–1178, 2014.

[8] C. M. Kusminski and P. E. Scherer, “Mitochondrial dysfunction in white adipose tissue,” Trends in Endocrinology and Metabolism, vol. 23, no. 9, pp. 435–443, 2012.

[9] J. H. Lee, Park, Oh, Lee, Kim, and Bae, “The role of adipose tissue mitochondria: regulation of mitochondrial function for the treatment of metabolic diseases,” International Journal of Molecular Sciences, vol. 20, no. 19, p. 4924, 2019.

[10] Q. Li, Z. Gao, Y. Chen, and M. X. Guan, “Impaired mitochondrial function in white adipose tissue, Protein & Cell, vol. 8, no. 6, pp. 439–445, 2017.

[11] Y. Zhang, G. Marsboom, P. T. Toth, and J. Rehman, "Mitochondrial respiration regulates adipogenic differentiation of human mesenchymal stem cells," PLoS One, vol. 8, no. 10, article e77077, 2013.

[12] K. V. Tormos, E. Anso, R. B. Hamanaka et al., “Mitochondrial complex III ROS regulate adipocyte differentiation,” Cell Metabolism, vol. 14, no. 4, pp. 537–544, 2011.

[13] R. H. Lu, H. Ji, Z. G. Chang, S. S. Su, and G. S. Yang, “Mitochondrial development and the influence of its dysfunction during rat adipocyte differentiation,” Molecular Biology Reports, vol. 37, no. 5, pp. 2173–2182, 2010.

[14] G. Medina-Gomez, “Mitochondria and endocrine function of adipose tissue,” Best Practice & Research. Clinical Endocrinology & Metabolism, vol. 26, no. 6, pp. 791–804, 2012.

[15] M. A. Aon, N. Bhatt, and S. C. Cortassa, “Mitochondrial and cellular mechanisms for managing lipid excess,” Frontiers in Physiology, vol. 5, article 282, 2014.

[16] Z. Ye, S. Wang, C. Zhang, and Y. Zhao, “Coordinated modulation of energy metabolism and inflammation by branched-chain amino acids and fatty acids,” Frontiers in endocrinology, vol. 11, article 617, 2020.

[17] T. Auguet, E. Guiu-Jurado, A. Berlanga et al., “Downregulation of lipogenesis and fatty acid oxidation in the subcutaneous adipose tissue of morbidly obese women,” Obesity (Silver Spring), vol. 22, no. 9, pp. 2032–2038, 2014.

[18] S. Heinonen, J. Buzkova, M. Muniandy et al., “Impaired mitochondrial biogenesis in adipose tissue in acquired obesity,” Diabetes, vol. 64, no. 9, pp. 3135–3145, 2015.

[19] S. Heinonen, M. Muniandy, J. Buzkova et al., “Mitochondria-related transcriptional signature is downregulated in adipocytes in obesity: a study of young healthy MZ twins,” Diabetologia, vol. 60, no. 1, pp. 169–181, 2017.

[20] K. H. Pietiläinen, J. Naukkarinen, A. Rissanen et al., “Global transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesity,” PLoS Medicine, vol. 5, no. 3, article e58, 2008.

[21] B. Fischer, T. Schöttl, C. Schempp et al., “Inverse relationship between body mass index and mitochondrial oxidative phosphorylation capacity in human subcutaneous adipocytes,” American Journal of Physiology. Endocrinology and Metabolism, vol. 309, no. 4, pp. E380–E387, 2015.

[22] X. Yin, I. R. Lanza, J. M. Swain, M. G. Sarr, K. S. Nair, and M. D. Jensen, “Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 2, pp. E209–E216, 2014.

[23] E. Yehuda-Shnайдman, B. Buehrer, J. Pi, N. Kumar, and S. Collins, “Acute stimulation of white adipocyte respiration by PKA-induced lipolysis,” Diabetes, vol. 59, no. 10, pp. 2474–2483, 2010.

[24] A. Mardinoglu, C. Kampf, A. Asplund et al., “Defining the human adipose tissue proteome to reveal metabolic alterations in obesity,” Journal of Proteome Research, vol. 13, no. 11, pp. 5106–5119, 2014.

[25] M. Muniandy, S. Heinonen, H. Yki-Järvinen et al., “Gene expression profile of subcutaneous adipose tissue in BMI-discordant monozygotic twin pairs unravels molecular and clinical changes associated with sub-types of obesity,” International Journal of Obesity, vol. 41, no. 8, pp. 1176–1184, 2017.

[26] A. Kuryłowicz and M. Puzianowska-Kuznicka, “Induction of adipose tissue browning as a strategy to combat obesity,” International Journal of Molecular Sciences, vol. 21, no. 17, article 6241, 2020.

[27] S. Cinti, “Transdifferentiation properties of adipocytes in the adipose organ,” American Journal of Physiology. Endocrinology and Metabolism, vol. 297, no. 5, pp. E977–E986, 2009.

[28] M. Giralt and F. Villarroya, “White, brown, beige/hite: different adipose cells for different functions?,” Endocrinology, vol. 154, no. 9, pp. 2992–3000, 2013.

[29] A. Park, W. K. Kim, and K. H. Bae, “Distinction of white, beige and brown adipocytes derived from mesenchymal stem cells,” World Journal of Stem Cells, vol. 6, no. 1, pp. 33–42, 2014.

[30] F. J. Ruiz-Ojeda, A. I. Ruperez, C. Gomez-Llortente, A. Gil, and C. M. Aguileria, “Cell models and their application for studying adipigenic differentiation in relation to obesity: a review,” International Journal of Molecular Sciences, vol. 17, no. 7, article 1040, 2016.

[31] J. Dufau, J. X. Shen, M. Couchet et al., “In vitro and ex vivo models of adipocytes,” American Journal of Physiology. Cell Physiology, vol. 320, no. 5, pp. C822–C841, 2021.

[32] A. J. Katz, R. Ilull, M. H. Hedrick, and J. W. Futrell, “Emerging approaches to the tissue engineering of fat,” Clinics in Plastic Surgery, vol. 26, no. 4, pp. 587–603, 1999.

[33] P. A. Zuk, M. Zhu, H. Mizuno et al., “Multilineage cells from human adipose tissue: implications for cell-based therapies,” Tissue Engineering, vol. 7, no. 2, pp. 211–228, 2001.

[34] C. Tiraby, G. Tavernier, C. Lefort et al., “Acqurement of brown fat cell features by human white adipocytes,” The Journal of Biological Chemistry, vol. 278, no. 35, pp. 33370–33376, 2003.

[35] I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, “Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo,” Diabetes, vol. 54, no. 5, pp. 1392–1399, 2005.

[36] N. Petrovic, T. B. Walden, I. G. Shabalina, J. A. Timmons, B. Cannon, and J. Nedergaard, “Chronic peroxisome proliferator-activated receptor γ (PPARγ) activation of epidermally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes,” The Journal of Biological Chemistry, vol. 285, no. 10, pp. 7153–7164, 2010.

[37] S. Bartesaghi, S. Hallen, L. Huang et al., “Thermogenic activity of UCP1 in human white fat-derived beige adipocytes,” Molecular Endocrinology, vol. 29, no. 1, pp. 130–139, 2015.
[38] D. F. Pisani, V. Barquissau, J. C. Chambard et al., “Mitochondrial fission is associated with UCP1 activity in human brite/beige adipocytes,” *Molecular Metabolism*, vol. 7, pp. 35–44, 2018.

[39] J. Y. Lee, N. Takahashi, M. Yasubuchi et al., “Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes,” *American Journal of Physiology. Cell Physiology*, vol. 302, no. 2, pp. C463–C472, 2012.

[40] M. J. Lee, S. Jash, J. E. C. Jones, V. Puri, and S. K. Fried, “Rosiglitazone remodels the lipid droplet and imparts human visceral and subcutaneous adipocytes ex vivo[S],” *Journal of Lipid Research*, vol. 60, no. 4, pp. 856–868, 2019.

[41] J. Gimble and F. Guilak, “Adipose-derived adult stem cells: isolation, characterization, and differentiation potential,” *Cytotherapy*, vol. 5, no. 5, pp. 362–369, 2003.

[42] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[43] M. J. Lee and S. K. Fried, “Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[44] N. A. Kraus, F. Ehebauer, B. Zapp, B. Rudolphi, B. J. Kraus, and M. J. Lee and S. Jash, “Adipogenic real-time quantitative PCR data,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[45] J. L. Pohjoismäki, S. Go, L. Z. Sharp, K. Shinoda, H. Ohno et al., “Uptake and mitochondrial DNA replication of exogenously derived human mesenchymal stem cells,” *Japanese Journal of Physiology. Endocrinology and Metabolism*, vol. 308, no. 12, pp. E1085–E1105, 2015.

[46] E. Järvinen, K. Ismail, M. Muniandy et al., “Improved endogenous mitochondrial expression and metabolic function,” *American Journal of Physiology. Cell Physiology*, vol. 308, no. 4, pp. C153–C159, 2010.

[47] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[48] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[49] M. J. Lee and S. K. Fried, “Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[50] N. A. Kraus, F. Ehebauer, B. Zapp, B. Rudolphi, B. J. Kraus, and M. J. Lee and S. Jash, “Adipogenic real-time quantitative PCR data,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[51] J. L. Pohjoismäki, S. Go, L. Z. Sharp, K. Shinoda, H. Ohno et al., “Uptake and mitochondrial DNA replication of exogenously derived human mesenchymal stem cells,” *Japanese Journal of Physiology. Endocrinology and Metabolism*, vol. 308, no. 12, pp. E1085–E1105, 2015.

[52] E. Järvinen, K. Ismail, M. Muniandy et al., “Improved endogenous mitochondrial expression and metabolic function,” *American Journal of Physiology. Cell Physiology*, vol. 308, no. 4, pp. C153–C159, 2010.

[53] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[54] M. J. Lee and S. K. Fried, “Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[55] N. A. Kraus, F. Ehebauer, B. Zapp, B. Rudolphi, B. J. Kraus, and M. J. Lee and S. Jash, “Adipogenic real-time quantitative PCR data,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[56] J. L. Pohjoismäki, S. Go, L. Z. Sharp, K. Shinoda, H. Ohno et al., “Uptake and mitochondrial DNA replication of exogenously derived human mesenchymal stem cells,” *Japanese Journal of Physiology. Endocrinology and Metabolism*, vol. 308, no. 12, pp. E1085–E1105, 2015.

[57] E. Järvinen, K. Ismail, M. Muniandy et al., “Improved endogenous mitochondrial expression and metabolic function,” *American Journal of Physiology. Cell Physiology*, vol. 308, no. 4, pp. C153–C159, 2010.

[58] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[59] M. J. Lee and S. K. Fried, “Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[60] N. A. Kraus, F. Ehebauer, B. Zapp, B. Rudolphi, B. J. Kraus, and M. J. Lee and S. Jash, “Adipogenic real-time quantitative PCR data,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[61] J. L. Pohjoismäki, S. Go, L. Z. Sharp, K. Shinoda, H. Ohno et al., “Uptake and mitochondrial DNA replication of exogenously derived human mesenchymal stem cells,” *Japanese Journal of Physiology. Endocrinology and Metabolism*, vol. 308, no. 12, pp. E1085–E1105, 2015.

[62] E. Järvinen, K. Ismail, M. Muniandy et al., “Improved endogenous mitochondrial expression and metabolic function,” *American Journal of Physiology. Cell Physiology*, vol. 308, no. 4, pp. C153–C159, 2010.

[63] M. Patrikioski, M. Juntunen, S. Boucher et al., “Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion,” *Biomaterials*, vol. 26, no. 31, pp. 6167–6175, 2005.

[64] M. J. Lee and S. K. Fried, “Optimal protocol for the differentiation and metabolic analysis of human adipose stromal cells,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[65] N. A. Kraus, F. Ehebauer, B. Zapp, B. Rudolphi, B. J. Kraus, and M. J. Lee and S. Jash, “Adipogenic real-time quantitative PCR data,” *Methods in Enzymology*, vol. 538, pp. 49–65, 2014.

[66] J. L. Pohjoismäki, S. Go, L. Z. Sharp, K. Shinoda, H. Ohno et al., “Uptake and mitochondrial DNA replication of exogenously derived human mesenchymal stem cells,” *Japanese Journal of Physiology. Endocrinology and Metabolism*, vol. 308, no. 12, pp. E1085–E1105, 2015.
and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs,” *The Journal of Biological Chemistry*, vol. 272, no. 6, pp. 3406–3410, 1997.

[70] A. Bernardo, M. A. Ajmon-Cat, L. Gasparini, E. Ongini, and L. Minghetti, “Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen,” *Journal of Neurochemistry*, vol. 92, no. 4, pp. 895–903, 2005.

[71] M. Styner, B. Sen, Z. Xie, N. Case, and J. Rubin, “Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism,” *Journal of Cellular Biochemistry*, vol. 111, no. 4, pp. 1042–1050, 2010.

[72] L. Wilson-Fritch, S. Nicoloro, M. Chouinard et al., “Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone,” *The Journal of Clinical Investigation*, vol. 114, no. 9, pp. 1281–1289, 2004.

[73] D. F. Pisani, M. Djedaini, G. E. Beranger et al., “Differentiation of human adipose-derived stem cells into “brite” (brown-in-white) adipocytes,” *Frontiers in Endocrinology*, vol. 2, article 87, 2011.

[74] H. Overby, Y. Yang, X. Xu, S. Wang, and L. Zhao, “Indomethacin promotes browning and brown adipogenesis in both murine and human fat cells,” *Pharmacology Research & Perspectives*, vol. 8, no. 3, article e00592, 2020.

[75] X. Wang, L. H. You, X. W. Cui et al., “Evaluation and optimization of differentiation conditions for human primary brown adipocytes,” *Scientific Reports*, vol. 8, no. 1, p. 5304, 2018.

[76] M. J. Harms, Q. Li, S. Lee et al., “Mature human white adipocytes cultured under membranes maintain identity, function, and can transdifferentiate into brown-like adipocytes,” *Cell Reports*, vol. 27, no. 1, pp. 213–225.e5, 2019, e5.

[77] L. Rui, “Brown and beige adipose tissues in health and disease,” *Comprehensive Physiology*, vol. 7, no. 4, pp. 1281–1306, 2017.

[78] F. Cioffi, R. Senese, A. Lanni, and F. Goglia, “Thyroid hormones and mitochondria: with a brief look at derivatives and analogues,” *Molecular and Cellular Endocrinology*, vol. 379, no. 1-2, pp. 51–61, 2013.

[79] P. Barbe, D. Larrouy, C. Boulanger et al., “Triiodothyronine-mediated up-regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without coordinated induction of mitochondrial respiratory chain genes,” *The FASEB Journal*, vol. 15, no. 1, pp. 13–15, 2001.

[80] N. Viguerie, L. Millet, S. Avizou, H. Vidal, D. Larrouy, and D. Langin, “Regulation of human adipocyte gene expression by thyroid hormone,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 87, no. 2, pp. 630–634, 2002.

[81] A. S. Divakaruni, A. Paradyse, D. A. Ferrick, A. N. Murphy, and M. Jastroch, “Analysis and interpretation of microplate-based oxygen consumption and pH data,” *Methods in Enzymology*, vol. 547, pp. 309–354, 2014.

[82] I. G. Shabalina, E. C. Backlund, J. Bar-Tana, B. Cannon, and J. Nedergaard, “Within brown-fat cells, UCP1-mediated fatty acid-induced uncoupling is independent of fatty acid metabolism,” *Biochimica et Biophysica Acta*, vol. 1777, no. 7-8, pp. 642–650, 2008.

[83] M. Liesa and O. S. Shirihai, “Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure,” *Cell Metabolism*, vol. 17, no. 4, pp. 491–506, 2013.

[84] A. S. Divakaruni and M. D. Brand, “The regulation and physiology of mitochondrial proton leak,” *Physiology (Bethesda)*, vol. 26, no. 3, pp. 192–205, 2011.

[85] J. D. Wikstrom, K. Mahdaviani, M. Liesa et al., “Hormone-induced mitochondrial fission is utilized by brown adipocytes as an amplification pathway for energy expenditure,” *The EMBO Journal*, vol. 33, no. 5, pp. 418–436, 2014.

[86] T. Wai and T. Langer, “Mitochondrial dynamics and metabolic regulation,” *Trends in Endocrinology and Metabolism*, vol. 27, no. 2, pp. 105–117, 2016.

[87] J. Wada and A. Nakatsuka, “Mitochondrial dynamics and mitochondrial dysfunction in diabetes,” *Acta Medica Okayama*, vol. 70, no. 3, pp. 151–158, 2016.

[88] W. Jiang, T. Miyamoto, T. Kakizawa et al., “Expression of thyroid hormone receptor alpha in 3T3-L1 adipocytes; triiodothyronine increases the expression of lipogenic enzyme and triglyceride accumulation,” *The Journal of Endocrinology*, vol. 182, no. 2, pp. 295–302, 2004.

[89] M. J. Obregon, “Thyroid hormone and adipocyte differentiation,” *Thyroid*, vol. 18, no. 2, pp. 185–195, 2008.